Compare Recursion Pharmaceuticals Inc (RXRX) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Western Digital Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Western Digital Corp trades at $554.05 (market cap $168.00B). The key difference: Western Digital Corp is far larger — about 109.8× Recursion Pharmaceuticals Inc's market cap, and Western Digital Corp pays a 0.12% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WDC | |
|---|---|---|
Market Cap | $1.53B | $168.00B |
Sector | Health | Technology |
52-Week High | $6.79 | $746.23 |
52-Week Low | $2.84 | $67.06 |
Enterprise Value | $946.50M | $166.35B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Western Digital (WDC) trades at $548.07, up 14.85% over 24 hours, reflecting strong momentum in memory stocks. The stock exhibits a bearish technical signal but has beaten earnings estimates for three consecutive quarters. Key financials show robust profitability with a net income margin of 55.07% and ROE of 37.73%. Recent news highlights WDC's position in the AI-driven memory and storage rebound, with institutional buying activity noted.
Outlook remains positive given analyst consensus and AI-driven demand, though valuation multiples are elevated. Risks include market volatility and competitive pressures. The consensus price target of $619.07 suggests potential upside, supported by strong institutional sentiment and fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
